Literature DB >> 22977588

Prediction of clinical outcome using p16INK4a immunocytochemical expression in low-grade squamous intraepithelial lesions and high-risk HPV-positive atypical squamous cells of undetermined significance in patients with and without colposcopic evident cervical disease.

Ankica Lukic1, Giorgio Sbenaglia, Elisabetta Carico, Matilde DI Properzio, Enrico Giarnieri, Antonio Frega, Flavia Nobili, Massimo Moscarini, Maria Rosaria Giovagnoli.   

Abstract

p16INK4a as a diagnostic marker of a cervical intraepithelial neoplasia of grade 2+ (CIN2+) in atypical squamous cells of undetermined significance (ASC-US) and low-grade squamous intraepithelial lesion (LSIL) cytological samples has been analyzed, but has not yet been included in clinical routine practice. One hundred and ninety-one patients with an abnormal Pap test (84 ASC-US and 107 LSILs) who underwent colposcopy were selected for this study. At enrollment, 96 patients (Group 1) had a positive colposcopy and therefore underwent a cervical biopsy, while 95 (Group 2) had a negative colposcopy and were followed up for up to 1 year. Both groups were tested for p16INK4a using immunocytochemical methods, and the p16INK4a results were correlated with histology or follow-up outcome. In Group 1 ASC-US cases, 82% of lesions less than CIN2 were p16INK4a-negative and all CIN2 cases were p16INK4a-positive (p=0.00044). In Group 1 LSIL cases, 71% of lesions less than CIN2 were p16INK4a-negative and 87% of CIN2/3 were p16INK4a-positive (p=0.00033). Seventy-seven percent of Group 2 ASC-US patients with a negative 1-year follow-up (NF-U) were p16INK4a-negative at enrollment, while all patients with positive follow-up (PF-U) were p16INK4a-positive (p=0.00113). In Group 2 LSIL cases, 83% of patients with NF-U were p16INK4a-negative, while 65% of patients with PF-U were p16INK4a-positive at enrollment (p=0.0014). In fact, 39% of the positive p16INK4a LSIL patients had CIN2+ histological lesions. The positive predictive value of p16INK4a for CIN2+ was 50% in ASC-US and 52% in LSIL cases; the negative predictive value was 100 and 94%, respectively. In conclusion, in our patients, a negative p16INK4a appears to be a marker of the absence of CIN3, while a positive p16INK4a can be correlated with the presence of histological CIN2+ found at enrollment or during the subsequent follow-up. Thus, its clinical predictive value is independent from the colposcopic aspect at enrollment.

Entities:  

Year:  2011        PMID: 22977588      PMCID: PMC3440826          DOI: 10.3892/etm.2011.316

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  34 in total

Review 1.  [Should CIN 2 and 3 be treated the same way?].

Authors:  X Carcopino; C Muszynski; J-L Mergui; J Gondry; L Boubli
Journal:  Gynecol Obstet Fertil       Date:  2011-02-16

Review 2.  Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma.

Authors:  Donna Dehn; Kathleen C Torkko; Kenneth R Shroyer
Journal:  Cancer       Date:  2007-02-25       Impact factor: 6.860

Review 3.  Papillomavirus infections--a major cause of human cancers.

Authors:  H zur Hausen
Journal:  Biochim Biophys Acta       Date:  1996-10-09

4.  Triage of women with ASCUS and LSIL cytology: use of qualitative assessment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia.

Authors:  Nicolas Wentzensen; Christine Bergeron; Frederic Cas; Svetlana Vinokurova; Magnus von Knebel Doeberitz
Journal:  Cancer       Date:  2007-02-25       Impact factor: 6.860

Review 5.  Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers.

Authors:  J P A Baak; A-J Kruse; S J Robboy; E A M Janssen; B van Diermen; I Skaland
Journal:  J Clin Pathol       Date:  2006-05-05       Impact factor: 3.411

Review 6.  Cyclin D-dependent kinases, INK4 inhibitors and cancer.

Authors:  Sagrario Ortega; Marcos Malumbres; Mariano Barbacid
Journal:  Biochim Biophys Acta       Date:  2002-03-14

7.  Antibody anti-p16(INK4a) in cervical cytology.

Authors:  Alexandre S Rocha; Mary C Bozzetti; Luciana S Kirschnick; Maria I A Edelweiss
Journal:  Acta Cytol       Date:  2009 May-Jun       Impact factor: 2.319

Review 8.  New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections.

Authors:  M von Knebel Doeberitz
Journal:  Eur J Cancer       Date:  2002-11       Impact factor: 9.162

9.  Are adjunctive markers useful in routine cervical cancer screening? Application of p16(INK4a) and HPV-PCR on ThinPrep samples with histological follow-up.

Authors:  D Schledermann; B T Andersen; K Bisgaard; M Dohse; D Ejersbo; B Hoelund; P Horal; M Lindh; W Ryd
Journal:  Diagn Cytopathol       Date:  2008-07       Impact factor: 1.582

10.  European guidelines for clinical management of abnormal cervical cytology, part 2.

Authors:  J Jordan; P Martin-Hirsch; M Arbyn; U Schenck; J-J Baldauf; D Da Silva; A Anttila; P Nieminen; W Prendiville
Journal:  Cytopathology       Date:  2009-02       Impact factor: 2.073

View more
  3 in total

1.  HPV16 E6*II gene expression in intraepithelial cervical lesions as an indicator of neoplastic grade: a pilot study.

Authors:  Dorota Pastuszak-Lewandoska; Anna Bartosińska-Dyc; Monika Migdalska-Sęk; Karolina H Czarnecka; Ewa Nawrot; Daria Domańska; Krzysztof Szyłło; Ewa Brzeziańska
Journal:  Med Oncol       Date:  2014-01-17       Impact factor: 3.064

Review 2.  Expression and role of p16 and GLUT1 in malignant diseases and lung cancer: A review.

Authors:  Aldo Pezzuto; Michela D'Ascanio; Alberto Ricci; Alessandra Pagliuca; Elisabetta Carico
Journal:  Thorac Cancer       Date:  2020-09-18       Impact factor: 3.500

3.  Makorin Ring Finger Protein 1 as Adjunctive Marker in Liquid-based Cervical Cytology.

Authors:  Maria Lee; Min Young Chang; Ha-Yeon Shin; Eunah Shin; Sun Won Hong; Kyung-Mi Kim; Doo Byung Chay; Hanbyoul Cho; Jae-Hoon Kim
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.